UY34274A - Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv). - Google Patents

Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).

Info

Publication number
UY34274A
UY34274A UY0001034274A UY34274A UY34274A UY 34274 A UY34274 A UY 34274A UY 0001034274 A UY0001034274 A UY 0001034274A UY 34274 A UY34274 A UY 34274A UY 34274 A UY34274 A UY 34274A
Authority
UY
Uruguay
Prior art keywords
hcv
hepatitis
infections
virus
treatment
Prior art date
Application number
UY0001034274A
Other languages
English (en)
Inventor
John Brad Shotwell
Andrew James Peat
Pek Yoke Chong
John F Miller
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34274(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY34274A publication Critical patent/UY34274A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Abstract

La presente invención proporciona los compuestos de la fórmula (I) y las sales de los mismos, composiciones farmacéuticas que comprenden estos compuestos, y el uso de estos compuestos en el tratamiento o en la prevención de infecciones virales, tales como las infecciones por el virus de hepatitis C (HCV), y las enfermedades asociadas con esas infecciones.
UY0001034274A 2011-08-19 2012-08-17 Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv). UY34274A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23

Publications (1)

Publication Number Publication Date
UY34274A true UY34274A (es) 2013-04-05

Family

ID=47746761

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034274A UY34274A (es) 2011-08-19 2012-08-17 Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).

Country Status (37)

Country Link
US (2) US8927593B2 (es)
EP (2) EP3199531A1 (es)
JP (2) JP6367712B2 (es)
KR (1) KR101913800B1 (es)
CN (1) CN103732065B (es)
AR (1) AR087563A1 (es)
AU (1) AU2012299295B2 (es)
BR (1) BR112014002845A2 (es)
CA (1) CA2844086A1 (es)
CL (2) CL2014000393A1 (es)
CO (1) CO6862153A2 (es)
CR (1) CR20140078A (es)
CY (1) CY1118399T1 (es)
DK (1) DK2744332T3 (es)
DO (1) DOP2014000034A (es)
EA (1) EA032841B1 (es)
ES (1) ES2611731T3 (es)
HR (1) HRP20161743T1 (es)
HU (1) HUE030300T2 (es)
IL (1) IL230487B (es)
IN (1) IN2014CN00572A (es)
JO (1) JO3281B1 (es)
LT (1) LT2744332T (es)
MA (1) MA35443B1 (es)
ME (1) ME02588B (es)
MX (1) MX354676B (es)
PE (1) PE20141201A1 (es)
PL (1) PL2744332T3 (es)
PT (1) PT2744332T (es)
RS (1) RS55462B1 (es)
SG (1) SG10201606883QA (es)
SI (1) SI2744332T1 (es)
SM (1) SMT201700028B (es)
TW (1) TWI538915B (es)
UY (1) UY34274A (es)
WO (1) WO2013028371A1 (es)
ZA (1) ZA201401020B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141391A1 (es) 2011-08-17 2014-10-29 Glaxosmithkline Llc Combinacion que comprende un compuesto con actividad antiviral y un agente terapeutico
CA2844086A1 (en) 2011-08-19 2013-02-28 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis c virus infections
EP3218486A1 (en) 2014-11-10 2017-09-20 Glaxosmithkline Intellectual Property (No. 2) Limited Combination long acting compositions and methods for hepatitis c
EA201790771A1 (ru) 2014-11-10 2017-11-30 Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед Фармацевтические композиции длительного действия для лечения гепатита c
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
US11738088B2 (en) 2016-08-01 2023-08-29 University of Pittsburgh—of the Commonwealth System of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
SG11201908012SA (en) * 2017-03-02 2019-09-27 Assembly Biosciences Inc Cyclic sulfamide compounds and methods of using same
AR114082A1 (es) * 2018-01-17 2020-07-22 Glaxosmithkline Ip Dev Ltd INHIBIDORES DE LA PI4KIIIb
EP4049680A4 (en) * 2019-10-25 2024-01-10 Sumitomo Pharma Co Ltd NEW SUBSTITUTED CONDENSED RING CONNECTION
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
EP1196436A2 (en) * 1999-07-07 2002-04-17 Bristol-Myers Squibb Pharma Company Peptide boronic acid inhibitors of hepatitis c virus protease
DK2251344T3 (en) 2001-01-25 2016-05-09 Us Of America Represented By The Secretary Dept Of Health And Human Services Formulation of boronic acid
NZ539727A (en) * 2002-11-01 2008-01-31 Viropharma Inc Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
JP2009519240A (ja) * 2005-12-01 2009-05-14 ワイス Ｃ型肝炎ウイルスの感染の治療に有用なアントラニル酸誘導体
KR101622870B1 (ko) 2006-02-16 2016-05-19 아나코르 파마슈티칼스 인코포레이티드 항염증제로서 보론함유 소분자
WO2007131072A2 (en) * 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
EP2520561B1 (en) * 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
JP2011512341A (ja) * 2008-02-14 2011-04-21 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環化合物
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
TW201138786A (en) 2010-02-19 2011-11-16 Glaxo Group Ltd Therapeutic compounds
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
AU2011329485A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
AU2011329486A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
PE20141391A1 (es) * 2011-08-17 2014-10-29 Glaxosmithkline Llc Combinacion que comprende un compuesto con actividad antiviral y un agente terapeutico
CA2844086A1 (en) 2011-08-19 2013-02-28 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis c virus infections

Also Published As

Publication number Publication date
IN2014CN00572A (es) 2015-04-03
CY1118399T1 (el) 2017-06-28
ME02588B (me) 2017-06-20
EP2744332A4 (en) 2015-01-14
JP2017125010A (ja) 2017-07-20
ZA201401020B (en) 2020-11-25
EA032841B1 (ru) 2019-07-31
JP2014527529A (ja) 2014-10-16
CA2844086A1 (en) 2013-02-28
EP2744332B1 (en) 2016-10-26
AU2012299295A1 (en) 2014-02-20
EP2744332A1 (en) 2014-06-25
MX354676B (es) 2018-03-15
KR20140054287A (ko) 2014-05-08
SI2744332T1 (sl) 2017-01-31
WO2013028371A1 (en) 2013-02-28
CL2017000293A1 (es) 2017-10-06
DK2744332T3 (en) 2017-01-16
IL230487A0 (en) 2014-03-31
IL230487B (en) 2019-06-30
PT2744332T (pt) 2017-01-24
JO3281B1 (ar) 2018-09-16
MX2014001989A (es) 2014-02-27
LT2744332T (lt) 2017-01-10
US20130237501A1 (en) 2013-09-12
AR087563A1 (es) 2014-04-03
TW201321390A (zh) 2013-06-01
MA35443B1 (fr) 2014-09-01
US20150080343A1 (en) 2015-03-19
KR101913800B1 (ko) 2018-11-01
SMT201700028B (it) 2017-03-08
HUE030300T2 (en) 2017-04-28
CL2014000393A1 (es) 2014-08-01
RS55462B1 (sr) 2017-04-28
CN103732065A (zh) 2014-04-16
CR20140078A (es) 2014-03-20
CN103732065B (zh) 2016-10-26
EA201490213A1 (ru) 2014-07-30
HRP20161743T1 (hr) 2017-02-24
PE20141201A1 (es) 2014-10-03
PL2744332T3 (pl) 2017-03-31
EP3199531A1 (en) 2017-08-02
US8927593B2 (en) 2015-01-06
SG10201606883QA (en) 2016-10-28
TWI538915B (zh) 2016-06-21
DOP2014000034A (es) 2014-06-01
BR112014002845A2 (pt) 2017-02-21
CO6862153A2 (es) 2014-02-10
ES2611731T3 (es) 2017-05-10
US9682999B2 (en) 2017-06-20
JP6367712B2 (ja) 2018-08-01
AU2012299295B2 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
UY34274A (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).
CY1124469T1 (el) Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων
EA201790630A1 (ru) Способы получения рибозидов
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
CO6561783A2 (es) Inhibidores del virus flaviviridae
CR20160123A (es) Inhibidores de polimerasa hcv
CR20150611A (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis por el virus de la hepatitis b
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
GT201600086A (es) Pirrolo[12-f][1,2,4]triazinas útiles para tratar infecciones por el virus sincitial respiratorio
EA201590943A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201690526A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201692219A1 (ru) Способы получения противовирусных соединений
CL2012002782A1 (es) Compuestos derivados de pirazol-4-il-heterociclil-carboxamida, inhibidores de los trastornos mediados por las quinasas pim-1, pim-2 y pim-3; composición farmacéutica; mètodo de tratamiento; y su uso para el tratamiento del càncer, trastornos inmunes, enfermedades cardiovasculares e infecciones virales , entre otros.
UY34824A (es) Nucleósidos de espirooxetano de uracilo
PH12015501017A1 (en) Alternative uses for hbv assembly effectors
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
CL2013001428A1 (es) Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
BR112014030639A2 (pt) inibidores macrocíclicos de vírus flaviviridae
BR112014030630A2 (pt) inibidores macrocíclicos de vírus flaviviridae
UY34472A (es) Derivados modificados de 4-fenil-piridina
CL2012002057A1 (es) Compuestos macrociclicos sustituidos, como inhibidores del virus de la hepatitis c; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, utiles como agente antivirales.
EA201792021A1 (ru) Ингибитор jak

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020